Advertisement
Advertisement
MRNA
Moderna, Inc. Common Stock
47.23
USDSponsored
-0.03
-0.06%
May 22, 11:29 UTC -4
Open
MRNA Earnings Reports
Positive Surprise Ratio
MRNA beat 21 of 30 last estimates.
70%
Next Report
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$100.98M
/-$2.12
Implied change from Q1 26 (Revenue/ EPS)
-74.04%
/-37.65%
Implied change from Q2 25 (Revenue/ EPS)
-28.89%
/-0.47%
Moderna, Inc. Common Stock earnings per share and revenue
On May 01, 2026, MRNA reported earnings of -3.40 USD per share (EPS) for Q1 26, beating the estimate of -4.04 USD, resulting in a 15.85% surprise. Revenue reached 389.00 million, compared to an expected 232.53 million, with a 67.29% difference. The market reacted with a -1.24% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -2.12 USD, with revenue projected to reach 100.98 million USD, implying an decrease of -37.65% EPS, and decrease of -74.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Satellos Bioscience Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.61
Actual
-$0.53
Surprise
+13.58%
aTyr Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.11
Surprise
+21.60%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Outlook Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.16
Surprise
-30.72%
Pasithea Therapeutics Corp. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.45
Actual
-$0.12
Surprise
+73.86%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Moderna, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Moderna, Inc. Common Stock reported EPS of -$3.40, beating estimates by 15.85%, and revenue of $389.00M, 67.29% above expectations.
How did the market react to Moderna, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -1.24%, changed from $45.94 before the earnings release to $45.37 the day after.
When is Moderna, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jul 30, 2026.
What are the forecasts for Moderna, Inc. Common Stock's next earnings report?
Based on 10
analysts, Moderna, Inc. Common Stock is expected to report EPS of -$2.12 and revenue of $100.98M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement